Extracellular matrix signalling molecules
Abstract
Polynucleotides encoding mammalian ECM signalling molecules affecting the cell adhesion, migration, and proliferation activities characterizing such complex biological processes as angiogenesis, chondrogenesis, and oncogenesis, are provided. The polynucleotide compositions include DNAs and RNAs comprising part, or all, of an ECM signalling molecule coding sequence, or biological equivalents. Polypeptide compositions are also provided. The polypeptide compositions comprise mammalian ECM signalling molecules, peptide fragments, inhibitory peptides capable of interacting with receptors for ECM signalling molecules, and antibody products recognizing Cyr61. Also provided are methods for producing mammalian ECM signalling molecules. Further provided are methods for using mammalian ECM signalling molecules to screen for, and/or modulate, disorders associated with angiogenesis, chondrogenesis, and oncogenesis: ex vivo methods for using mammalian ECM signalling molecules to prepare blood products are also provided.
Claims
exact text as granted — not AI-modified1 - 64 . (canceled)
65 . A humanized monoclonal antibody that binds specifically to native human Cyr61.Join the waitlist — get patent alerts
Track US2006257965A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.